Skip Navigation

Cardiovascular Research 2003 58(3):555-564; doi:10.1016/S0008-6363(03)00251-7
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cittadini, A.
Right arrow Articles by Saccà, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cittadini, A.
Right arrow Articles by Saccà, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure

Antonio Cittadinia,*, Maria Gaia Montia, Jörgen Isgaardb, Cosma Casaburia, Hinrik Strömerc, Angela Di Giannia, Raffaella Serpicoa, Lavinia Saldamarcoa, Massimo Vanasiad and Luigi Saccàa

aDepartment of Internal Medicine and Cardiovascular Sciences, University Federico II, Naples, Italy
bResearch Center for Endocrinology and Metabolism, Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
cMedizinische Universitätsklinik Würzburg, Würzburg, Germany
dGiEnne Pharma, Milan, Italy

cittadin{at}unina.it

* Corresponding author. Medicina Interna, Via Pansini 5 (Ed. 18), University Federico II, 80131 Naples, Italy. Tel.: +39-081-746-4375; fax: +39-081-746-3199.

Objectives: To investigate the effects of aldosterone receptor blockade in postinfarction heart failure. Methods: Eighty-seven rats with moderate myocardial infarction were randomized to receive either no drug or canrenone, the active metabolite of spironolactone, 20 mg/kg/day, or ramipril, 1 mg/kg/day, or a combination of the two drugs. Treatment was initiated 1 month after coronary ligation and lasted 4 weeks. Echocardiography was performed at baseline and after 4 weeks. LV catheterization, isolated heart studies, morphometric histology, myocardial norepinephrine and SERCA-2 mRNA were assessed at the end of the treatment period. Results: Infarct sizes were 33±3, 32±3, 34±3, and 34±4% in the placebo, canrenone, ramipril, and combination groups, respectively. Canrenone attenuated LV remodeling, improved LV systolic and diastolic function, and markedly reduced interstitial and perivascular fibrosis. These effects were increased by concomitant ramipril therapy. Moreover, myocardial norepinephrine content was decreased while ventricular fibrillation threshold significantly augmented by canrenone. SERCA-2 levels remained unchanged. Conclusions: Canrenone attenuated LV dilation and interstitial remodeling, and improved LV filling dynamics and systolic function in the rat model of postinfarction heart failure. Addition of ramipril conferred further cardioprotection. Canrenone also reduced myocardial norepinephrine content and increased ventricular fibrillation threshold. The data provide a potential explanation for the decreased sudden death observed in the RALES study.

The mechanisms of action of aldosterone inhibition are still poorly understood, despite its proven efficacy in heart failure. Rats with postinfarction heart failure were randomized to receive for 1 month either no drug or canrenone, or ramipril, or a combination of canrenone and ramipril. Canrenone treatment was associated with a significant attenuation of LV dilation, better LV diastolic and systolic dynamics, and a marked reduction of reactive fibrosis. These effects were enhanced by concomitant ramipril therapy. Moreover, canrenone increased ventricular fibrillation threshold and reduced myocardial norepinephrine content. The data may explain the reduced mortality demonstrated by the RALES.

KEYWORDS Antagonists; Connective tissue; Fibrosis; Heart failure; Ventricular arrhythmias


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
Y. Sun
Myocardial repair/remodelling following infarction: roles of local factors
Cardiovasc Res, February 15, 2009; 81(3): 482 - 490.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. Boccanelli, G. F. Mureddu, G. Cacciatore, F. Clemenza, A. Di Lenarda, A. Gavazzi, M. Porcu, R. Latini, D. Lucci, A. P. Maggioni, et al.
Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results
Eur J Heart Fail, January 1, 2009; 11(1): 68 - 76.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. F. Rossier, S. Lenglet, L. Vetterli, M. Python, and A. Maturana
Corticosteroids and Redox Potential Modulate Spontaneous Contractions in Isolated Rat Ventricular Cardiomyocytes
Hypertension, October 1, 2008; 52(4): 721 - 728.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
K. Anand, A. N Mooss, and S. M Mohiuddin
Review: Aldosterone Inhibition Reduces the Risk of Sudden Cardiac Death in Patients with Heart Failure
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 15 - 19.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.